// App-Quantinova.ai

1656 : Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial

Researchers

Presenter

  • David D'Cruz

Principal Investigators

  • Anca Askanase

  • Ouali Berkani

  • clélia Cahuzac

  • peter Cornelisse

  • Kenneth Kalunian

  • Joan Merrill

  • Marilia Pozzobon

  • Sandra Navarra

Medical Centers

  • Columbia University Medical Center, New York, NY

  • IDORSIA, Allschwil, Switzerland

  • Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of California, San Diego, La Jolla, CA

  • Oklahoma Medical Research Foundation, Oklahoma city, OK.

  • University of Santo Tomas Hospital, Manila, Philippines

Locations

  • United States

  • Switzerland

  • United Kingdom

  • Philippines

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Blood/haematological Diseases

Disease

  • Lupus

  • Lymphocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • NCT03742037

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved